Dietrich Stephan, Founder, CEO, SV Bio Bio and Contact Info
Listen (5:24) What makes this the right time for SV Bio?
Listen (6:03) What does the SV Bio product look like?
Listen (2:38) Healthcare IT behind by several decades
Listen (6:52) How are you selling your product?
Listen (6:11) Whole genome pricing level still uncertain
Listen (5:02) The big ambition
On January 15th of this year a new company, Silicon Valley Biosystems, or SV Bio, was launched in the clinical genome interpretation space. And just this past week the company's lab gained CLIA certification. Founder and CEO, Dietrich Stephan was the creator several years back of Navigenics, a direct-to-consumer approach to personalized medicine. Navigenics was acquired by Life Technologies in the summer of last year. Stephan is quoted in Bio-It World as saying he “wanted to hit the refresh button and do the necessary inventing around rare variants now that the time is right.” Today he joins us to share his ambition for what he considers THE scalable platform and tell us why the time is right for SV Bio and genomic medicine.
Podcast brought to you by: Myraqa Clinical Research: The CRO for Point of Care and PMA Diagnostics.and by: Roche Molecular Systems: A proud sponsor of today's podcast.